Alemtuzumab-induced thyroid disease: A Danish cohort study
Data from the largest Danish MS center supports previous observations of unusual, long-lasting and unpredictable courses of alemtuzumab-induced GD. Thus, follow-up of these patients may require long lasting and more frequent biochemical measurements compared to other patients with GD. Also, concomitant block and replace treatment or definitive treatment, such as thyroidectomy, should be considered in a subgroup of patients.
Authors
- Finn Thorup Sellebjerg (ORCID: https://orcid.org/0000-0002-1333-9623)
- Melinda Magyari (ORCID: https://orcid.org/0000-0002-0972-5222)
- Ulla Feldt‐Rasmussen (ORCID: https://orcid.org/0000-0002-5903-3355)
- Åse Krogh Rasmussen (ORCID: https://orcid.org/0000-0002-9729-4767)
- Juliana Frohnert Hansen
Institutions
- University of Copenhagen (DK)
- Amager Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Multiple Sclerosis Center (DK)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.msard.2024.105880
- Citations
- 5
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Scleroseforeningen
- Moderna
- Multiple Sclerosis Society
- H. Lundbeck A/S
- Sanofi Genzyme